DV
Dividend Vision

CYTK — Cytokinetics, Incorporated

Cytokinetics, Incorporated (CYTK)

Total return is 360.4% over the past 22.3 years, 584.5 points behind SPY at 944.9%. Its deepest 1-year drawdown was 15.8%.

CYTK is an equity stock that does not function as a traditional ETF or dividend-focused investment vehicle. The company operates in the biotechnology sector and does not currently pay distributions to shareholders, resulting in no yield profile or dividend income component. This security is oriented toward investors seeking potential capital appreciation rather than those primarily focused on dividend income.

CYTK key facts

Asset type
Stock
Asset class
Equity
Inception date
04/29/2004
Distribution frequency
None
Last close
$74.13
Market cap
$10,305,806,336
Average volume
1756900.0
Beta
0.376
Payout ratio
0.0
Forward P/E
117.6471
EPS
$-7.22